Overview
To evaluate the time of response, sustained remission rate and relapse rate of CD38 monoclonal antibody (Daratumumab) combined corticosteroid in the treatment of AHA. To evaluate the safety of CD38 monoclonal antibody in the treatment of AHA.
Description
This is a prospective ,single-arm, multi-center controlled pilot trial of CD38 (Daratumumab) monoclonal antibody combined corticosteroid in the treatment of AHA patients.
Patients will receive Daratumumab and corticosteroid treatment in this trial.
Eligibility
Inclusion Criteria:
- Patients must meet all enrollment criteria before they can be enrolled:
Diagnosed as AHA; Women are postmenopausal women or women of childbearing age with strict
contraception; Patients with good compliance
Exclusion Criteria:
- Patients with any of the following items cannot be enrolled in this study:
Congenital hemophilia with inhibitor; Pregnant and lactating women; Who are positive for
hepatitis B surface antigen, hepatitis C antibody, HIV antibody (Ⅰ + Ⅱ) and syphilis
antibody; Patients with poor compliance; Who cannot use contraception during the trial;
Researchers believe that it is not appropriate for patients to participate in any other
condition of this trial; Four weeks before entering the group, the patients received
immunosuppressive therapy and the inhibitor showed a progressive decreasing trend (the
change was less than 50%).
Acquired von Willebrand disease